Technology
Health
Biotechnology

Navidea Biopharmaceuticals

$1.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.00 (-0.28%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NAVB and other stocks, options, ETFs, and crypto commission-free!

About

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. Read More The company was founded in 1983 and is headquartered in Dublin, OH.

Employees
19
Headquarters
Dublin, Ohio
Founded
1983
Market Cap
13.91M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
488.14K
High Today
$1.44
Low Today
$1.38
Open Price
$1.44
Volume
2.54K
52 Week High
$2.84
52 Week Low
$0.1005

Collections

Technology
Health
Biotechnology
Therapy
US
North America

News

Yahoo FinanceMay 11

Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT

Q1 2019 Navidea Biopharmaceuticals Inc Earnings Call DUBLIN May 12, 2019 (Thomson StreetEvents) -- Edited Transcript of Navidea Biopharmaceuticals Inc earnings conference call or presentation Wednesday, May 8, 2019 at 9:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Erika Gibson Navidea Biopharmaceuticals, Inc. - Director of...

61
Yahoo FinanceMay 8

Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)-- Conference Call to be held Wednesday, May 8, 2019 at 5:00 pm ET Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter of 2019. Navidea reported total revenues for the quarter of $136,000. Net loss attributable to common stockholders was $2.4 million. “During the first quarter, Navidea re...

89
Yahoo FinanceMay 1

Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

DUBLIN, Ohio--(BUSINESS WIRE)-- Conference Call to be held Wednesday, May 8, 2019 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, May 8, 2019 at 5:00 p.m. (EDT) to discuss its financial results for the first quarter of 2019. Jed Latkin, Chief Executive Officer, Erika Gibson, Direct...

200

Earnings

-$0.24
-$0.16
-$0.08
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.